NanoImaging Services Receives $1.5 Million in Venture Funding from Merck Capital Ventures
News Feb 27, 2008
NanoImaging Services, Inc. has completed a round of financing led by Merck Capital Ventures, LLC. The $1.5 million investment will be used to expand the company’s service laboratory. NanoImaging Services, currently located in Northern San Diego, will relocate to a larger facility in La Jolla, Calif. next month.
“Advanced TEM imaging allows biopharmaceutical manufacturers to actually see the complex macromolecular structures they create, in three dimensions, with resolution as high as one nanometer,” said Clint Potter, NanoImaging’s CEO.
“It provides powerful visual support for structural characterization and validation throughout the drug development pipeline—promising to shorten development cycles and improve confidence at every stage from discovery, through development and regulatory review, and into long-term quality control and manufacturing process improvement,” Potter added.
“NanoImaging Services has established a unique combination of advanced technology and world-class expertise in large molecule visualization and analysis,” said Per Lofberg, President and CEO of Merck Capital Ventures. “With its straightforward commercial service model, and the potential to accelerate candidate development, the company is well-positioned for leadership in supporting the pharmaceutical industry in the field of large molecule biologics.”
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE